Nivalis Therapeutics' Mezzanine Round

Nivalis Therapeutics raised a round of funding on November 19, 2014.

Nivalis Therapeutics, formerly N30Pharma, is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule wit…

Articles about Nivalis Therapeutics' Mezzanine Round: